Skip to content

Meet Our Faculty

David Gorski, MD, PhD, FACS

Chief, Division of Breast Surgery
Associate Professor of Surgery and Oncology, Wayne State University School of Medicine
Medical Director, Alexander J. Walt Comprehensive Breast Center, Barbara Ann Karmanos Cancer Institute
Office Address:
Karmanos Cancer Center
4100 John R, M/C HWO8AO
Detroit, MI 48201
Phone: (313) 576-8490
Fax: (313) 745-8480

Administrative Assistant: Lisa Berant
Administrative Email: berantl@karmanos.org

SPECIALTY: Breast and Oncologic Surgery
CLINICAL INTERESTS:

Breast and Oncologic Surgery

Education

BOARD CERTIFICIATIONS:
– American Board Of Surgery Board Certified

EDUCATION:
– Ph.D. – Cellular Physiology, Case Western Reserve University, Cleveland, OH
– M.D. – University of Michigan Medical School, Ann Arbor, Michigan
– B.S. – University of Michigan, Ann Arbor, MI

RESIDENCY:
– General Surgery Residency, University Hospitals of Cleveland, Case Western Reserve University School of Medicine, Cleveland, OH

FELLOWSHIPS:
– Surgical Oncology Research Fellowship, University of Chicago, Chicago, IL

Publications

  1. Racial differences in estrogen receptor staining levels and implications for treatment and survival among estrogen receptor positive, HER2-negative invasive breast cancers. Purrington KS, Gorski D, Simon MS, Hastert TA, Kim S, Rosati R, Schwartz AG, Ratnam M.Breast Cancer Res Treat. 2020 May;181(1):145-154. doi: 10.1007/s10549-020-05607-4. Epub 2020 Mar 31.PMID: 32236827
  2. Using Whole Breast Ultrasound Tomography to Improve Breast Cancer Risk Assessment: A Novel Risk Factor Based on the Quantitative Tissue Property of Sound Speed. Duric N, Sak M, Fan S, Pfeiffer RM, Littrup PJ, Simon MS, Gorski DH, Ali H, Purrington KS, Brem RF, Sherman ME, Gierach GL.J Clin Med. 2020 Jan 29;9(2):367. doi: 10.3390/jcm9020367.PMID: 32013177 Free PMC article.
  3. The Epidemiology of Cancer Among Homeless Adults in Metropolitan Detroit. Folowatyj AN, Heath EI, Pappas LM, Ruterbusch JJ, Gorski DH, Triest JA, Park HK, Beebe-Dimmer JL, Schwartz AG, Cote ML, Schwartz KL.JNCI Cancer Spectr. 2019 Mar;3(1):pkz006. doi: 10.1093/jncics/pkz006. Epub 2019 Mar 25.PMID: 30944890 Free PMC article.
  4. Metabotropic glutamate receptor-1 regulates inflammation in triple negative breast cancer. Sexton RE, Hachem AH, Assi AA, Bukhsh MA, Gorski DH, Speyer CL.Sci Rep. 2018 Oct 30;8(1):16008. doi: 10.1038/s41598-018-34502-8.PMID: 30375476 Free PMC article.
  5. IgA Fc-folate conjugate activates and recruits neutrophils to directly target triple-negative breast cancer cells. Frontera ED, Khansa RM, Schalk DL, Leakan LE, Guerin-Edbauer TJ, Ratnam M, Gorski DH, Speyer CL.Breast Cancer Res Treat. 2018 Dec;172(3):551-560. doi: 10.1007/s10549-018-4941-5. Epub 2018 Aug 28.PMID: 30155754 Free PMC article.
  6. Racial Differences in 21-Gene Recurrence Scores Among Patients With Hormone Receptor-Positive, Node-Negative Breast Cancer. Holowatyj AN, Cote ML, Ruterbusch JJ, Ghanem K, Schwartz AG, Vigneau FD, Gorski DH, Purrington KS.J Clin Oncol. 2018 Mar 1;36(7):652-658. doi: 10.1200/JCO.2017.74.5448. Epub 2018 Jan 17.PMID: 29341832 Free PMC article.
  7. Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer. Speyer CL, Bukhsh MA, Jafry WS, Sexton RE, Bandyopadhyay S, Gorski DH.Breast Cancer Res Treat. 2017 Nov;166(2):407-419. doi: 10.1007/s10549-017-4435-x. Epub 2017 Aug 5.PMID: 28780701 Free PMC article.
  8. Variation in the use of advanced imaging at the time of breast cancer diagnosis in a statewide registry. Henry NL, Braun TM, Breslin TM, Gorski DH, Silver SM, Griggs JJ.Cancer. 2017 Aug 1;123(15):2975-2983. doi: 10.1002/cncr.30674. Epub 2017 Mar 16.PMID: 28301680 Free article.
  9. Associations between use of the 21-gene recurrence score assay and chemotherapy regimen selection in a statewide registry. Henry NL, Braun TM, Ali HY, Munir K, Silver SM, Gorski DH, Breslin TM, Griggs JJ.Cancer. 2017 May 15;123(6):948-956. doi: 10.1002/cncr.30429. Epub 2016 Oct 27.PMID: 27787892 Free article.
  10. Strategic Endothelial Cell Tube Formation Assay: Comparing Extracellular Matrix and Growth Factor Reduced Extracellular Matrix. Xie D, Ju D, Speyer C, Gorski D, Kosir MA.J Vis Exp. 2016 Aug 14;(114):54074. doi: 10.3791/54074.PMID: 27585062 Free PMC article.

CLINICAL STUDIES:

  • PI – A Prognostic Study of Sentinel Node and Bone Marrow Metastases in Women with Clinical T1 or T2 N0 M0 Breast Cancer, 2009-present.
  • PI – A Randomized Trial of Axillary Node Dissection in Women With Clinical T1 or T2 N0 M0 Breast Cancer Who Have A Positive Sentinel Node, 2009-present.
  • PI – A Randomized Phase III Trial Comparing 16 to 18 Weeks of Neoadjuvant Exemestane (25mg daily), Letrozole (2.5 mg), or Anastrozole (1 mg) in Postmenopausal Women with Clinical Stage II and III Estrogen Receptor Positive Breast Cancer, 2009-present.
  • Co- Chair – ECOG Protocol #2301: A Randomized Phase II Study of BMS-247550 (NSC #710428) Given Daily x 5 Days Every 3 Weeks or Weekly in Patients with Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck, 2003-2005.

Teaching

MEDICAL STUDENTS:
Instruction in breast surgery clinic, lecturer on breast cancer, thesis committee

RESIDENTS:
Bedside teaching in hospital/clinic, didactic/socratic